Jones Pharma Incorporated has issued a `Dear Healthcare Professional' letter advising of changes to the US labelling of Levoxyl [levothyroxine sodium].

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1023, 2004-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Amgen Inc. has issued a `Dear Health Care Professional' letter advising of important changes to the labelling for Aranesp

By  

Reactions Weekly, Vol. 1, Iss. 1035, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Health Canada has issued both a Public Communication and a `Dear Healthcare Professional' letter advising of updated safety information for Invirase [saquinavir]

By  

Reactions Weekly, Vol. 1, Iss. 1327, 2010-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Eli Lilly has issued a `Dear Healthcare Professional' letter to advise of a new warning on the US Xigris [drotrecogin alfa] label

By  

Reactions Weekly, Vol. 1, Iss. 1044-1045, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Sanofi-aventis has issued a `Dear Healthcare Professional' letter outlining changes to the Ketek [telithromycin] label

By  

Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

The US FDA has issued a Talk Paper advising of changes to the US Strattera [atomoxetine] labelling

By  

Reactions Weekly, Vol. 1, Iss. 1033, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite